诺和诺德(NVO)

搜索文档
Pfizer Tries to Fatten Its Profits With Weight Loss Drugs
Investing· 2025-09-25 18:09
Market Analysis by covering: Eli Lilly and Company, Pfizer Inc, Novo Nordisk A/S, Metsera Inc. Read 's Market Analysis on Investing.com ...
辉瑞49亿美元收购成立三年的减肥药企,赌一个“弯道超车”的可能
观察者网· 2025-09-25 17:34
【文/王力 编辑/周毅】 当诺和诺德凭借司美格鲁肽系列产品在减肥药市场攫取百亿美元收入时,传统制药巨头们也逐渐加入这场角逐战。 9月22日,辉瑞宣布以49亿美元现金收购生物技术公司Metsera,这家成立仅三年的公司拥有四个处于临床阶段的肥胖治疗项目。这笔交易不仅标志着辉瑞正 式进军千亿美元规模的减肥药赛道,更预示着全球肥胖治疗市场即将迎来新一轮的竞争洗牌。 在诺和诺德的Wegovy占据60.7%市场份额、礼来Zepbound紧随其后的格局下,辉瑞的入局时机看似滞后。然而,通过收购拥有差异化产品管线的Metsera, 辉瑞试图以"每月给药"、"联合疗法"等创新优势实现弯道超车。 辉瑞CEO Albert Bourla直言:"肥胖是一个巨大且不断增长的领域,与之相关的健康状况超过200种。"这场收购案背后,隐藏着整个行业转型升级的深层密 码,也将重新定义全球减肥药市场的竞争格局。 辉瑞重金入局:49亿美元收购背后的战略考量 辉瑞对Metsera的收购堪称近年来减肥药领域最重磅的并购案之一。 根据协议条款,辉瑞将以每股47.50美元的现金价格收购Metsera全部流通股,交易总价值约49亿美元。更值得关注的是,该 ...
Denmark's 'Novo Town' holds its breath as Wegovy fever fades
Reuters· 2025-09-25 14:09
In Denmark's seaside town of Kalundborg, also known as "Novo Town", therapist Heidi Thron Rune has learnt to live with the noise of building work as new facilities take shape to meet demand for Novo Nordisk's Wegovy weight-loss drug. ...
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th
Globenewswire· 2025-09-25 05:23
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Novo (NVO) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Novo between May 7, 2025, to July 28, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel ...
Novo Nordisk A/S (NVO) Attracts Park Avenue Securities Investment
Yahoo Finance· 2025-09-25 04:37
Novo Nordisk A/S (NYSE:NVO) is among the best safe stocks to buy now. Park Avenue Securities LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) through the purchase of 85,970 shares of the company’s stock during the second quarter. According to the recent filing with the SEC, the firm’s investment in the company amounts to $5,934,000. Despite downgrades in outlook discouraging investors from acquiring the stock, there’s much to like about Novo Nordisk A/S (NYSE:NVO). The company has shown encouraging ...
LLY vs. NVO: Which Obesity Drug Stock Is the Better Buy Now?
ZACKS· 2025-09-25 01:25
Key Takeaways Lilly's Mounjaro and Zepbound now drive about half of its total revenues.Novo Nordisk cut 2025 guidance as Wegovy and Ozempic face supply and pricing pressures.LLY forecasts $60B-$62B revenues in 2025, up over 30% year over year.Novo Nordisk (NVO) and Eli Lilly (LLY) dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, tirzepatide, as Mounjaro for type II diabetes and as Zepbound for obes ...
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
Prnewswire· 2025-09-24 22:05
If you suffered losses exceeding $100,000 in Novo between May 7, 2025, to July 28, 2025and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983- 9330Â (Ext. 1310). [You may also click here for additional information] NEW YORK, Sept. 24, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) and reminds investors of the S ...
司美格鲁肽中国专利即将到期,诺和诺德加速推进口服减重药上市
第一财经· 2025-09-24 20:10
2025.09. 24 本文字数:1531,阅读时长大约3分钟 作者 | 第一财经 钱童心 2026年,丹麦制药巨头诺和诺德的明星减重药司美格鲁肽核心分子在中国的专利即将到期,届时, 该药物将面临大量来自中国仿制药的竞争。在这一背景下,诺和诺德正在积极推动口服版司美格鲁肽 减重药在全球的上市进程。 近日,诺和诺德在《新英格兰医学杂志》(NEJM)上发表一项最新三期临床数据,试验评估了在研 的每日一次口服司美格鲁肽片(25mg片剂)的有效性和安全性。结果显示,在服药64周时,口服司 美格鲁肽片25mg组患者实现了16.6%的平均体重降幅,患者中有1/3以上(34.4%)实现了20% 及以上的体重降幅,减重效果与司美格鲁肽注射液相当。 诺和诺德已于今年2月向美国FDA递交了每日一次司美格鲁肽25mg片剂的新药申请。该公司预计, FDA将于今年年底完成审批,届时该药物也有望成为全球首个获批上市的用于减重的GLP-1口服片 剂。诺和诺德还称,如获FDA批准,司美格鲁肽口服片剂将在美国境内制造。 口服司美格鲁肽上市将有助于诺和诺德占领口服减重药的市场先机。在全球市场上,该公司不仅面临 着主要竞争对手礼来的挑战,还有来自 ...